Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Medical Weekly, [S. l.], v. 149, n. 5152, p. w20170, 2019. DOI: 10.4414/smw.2019.20170. Disponível em: https://www.smw.ch/index.php/smw/article/view/2711. Acesso em: 14 oct. 2025.